Hyundai Pharmaceutical현대약품
004310 · KOSPI · ₩004310 · 현대약품
₩6,850▲ ₩150 (2.24%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩192B | ₩176B | ₩181B | ₩163B | ₩140B |
| Cost of sales | ₩112B | ₩102B | ₩104B | ₩94B | ₩83B |
| Gross profit | ₩80B | ₩73B | ₩77B | ₩69B | ₩56B |
| Operating income | ₩4.2B | ₩181M | ₩6.9B | ₩8B | −₩1.6B |
| Net income | ₩2.5B | −₩575M | ₩6.1B | −₩165M | −₩3.2B |
| Net income to shareholders | ₩2.5B | −₩575M | ₩6.1B | −₩165M | −₩3.2B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩163B | ₩156B | ₩155B | ₩181B | ₩164B |
| Current assets | ₩81B | ₩80B | ₩85B | ₩102B | ₩85B |
| Cash and equivalents | ₩2.5B | ₩10B | ₩16B | ₩30B | ₩22B |
| Total liabilities | ₩81B | ₩77B | ₩70B | ₩95B | ₩77B |
| Current liabilities | ₩71B | ₩59B | ₩65B | ₩81B | ₩46B |
| Borrowings | ₩50B | ₩48B | ₩38B | ₩39B | ₩29B |
| Total equity | ₩82B | ₩79B | ₩85B | ₩87B | ₩87B |
| Shareholders' equity | ₩82B | ₩79B | ₩85B | ₩87B | ₩87B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩123M | −₩2.4B | −₩4.5B | ₩12B | ₩5.1B |
| Capital spending | ₩4.6B | ₩9.8B | ₩4.6B | ₩2.4B | ₩1.3B |
| Free cash flow | −₩4.7B | −₩12B | −₩9.1B | ₩9.2B | ₩3.8B |
| Dividends paid | ₩784M | −₩923M | ₩826M | ₩836M | ₩1.2B |
Consolidated where available. Amounts in won.
Also known as: Hyundai Pharmaceutical / 현대약품 / 004310 / KRX:004310
Source: KRX statistical information